Subject Index. DAS, see Disability Assessment Schedule

Transcription

1 Acedia 79 Acetylcholine release 387 Adjustment -, premorbid 131, 155, , social 135 Adolescent - psychiatry schizophrenia 221 Aetiology -, heterogeneity 250 Affect 244, constricted flattening 35, 164, inappropriate 35 Age at onset , ,232 Akathisia 322 Ambivalence 269 AMDP, see Association for Methodology and Documentation in Psychiatry system Amotivational state Amphetamine 319, 320, , 331 -, drug abuse 93 Amygdala 296, 307 Anergia 332, 412 Anhedonia 79-95, 130, 165, 276, 317 -, antipsychotic medication , discriminative validity 92 -, physical 80 -, social 80 -, temporal stability 92 Apathy 80, 165, syndrome Apomorphine 110, 319, 380 Asociality 82 Assessment - of negative symptoms 28-70, , reliability 29-34, , validity 58 - of positive symptoms , reliability Association for Methodology and Documentation in Psychiatry System 54, Association, loss of 269 Ataxia, social 103 Attention 165, 234, 403 Autarky, impairment of 215 Autism 244, 269 Autoreceptor, see Dopamine Autoreceptor Avoliton Basal ganglia 292, 294 Basic disorder 139, 403 Biology Biochemical factors 292 BPRS, see Brief Psychiatric Rating Scale Brain - abnormalities - -, functional 46-48, 131, 134, 305, , , structural 45-46, 131, imaging studies morphology 121 Brief Psychiatric Rating Scale 54, 129, 322, 369, 412 Brockton-Harvard Project 280 Catatonia 292 Catecholamine 330 CATEGO 162 Cellae medias 303 Cerebral - blood flow 48, 305, 307, spinal fluid 318, 326, 332, 333 Child psychiatry ,454,455 Childhood psychoses , age of first manifestation , classification 219 -, course 220 -, development state 219 -, early-onset schizophrenia 247 -, late-onset psychoses 221 -, premorbid personality 221 -, sex differences 222 Cholecystokinin 321 Classification -, multiaxial scheme (lcd 9) of childhood psychoses 319

2 462 Clinical-anatomical correlations 296, 304 Clonidin 331 Clozapine Cocaine, drug abuse 93 Cognitive - disturbances 232, 276, treatment of negative symptoms 402 Cologne long-term study Concept - of inhibition - of positive and negative schizophrenia 128,, , history 8-29, in adolescent psychiatry in child psychiatry of positive and negative symptoms , external valida tors , history 8-29, , validity of schizophrenia Conceptual history of positive and negative signals 8-27 Coping behavior 141,400,416, Corpus callosum 294, 303 Correlations - of positive and negative symptoms Cortex -, frontal 131,294, , parietal , prefrontal 317, 320 Course models of adolescent schizophrenia of childhood schizophrenia of mixed schizophrenia , - of negative schizophrenia , - of positive schizophrenia , - of positive and negative symptoms ,221 -, shift of symptoms , 223 -,stability Cranial size 303 Criteria -, negative schizophrenia 225 -, positive schizophrenia 225 CSF, see Cerebral spinal fluid CT scan studies 45, Cytoarchitectural changes 296, 308 DAS, see Disability Assessment Schedule Defect -, neurointegrative 84 -, schizophrenic 135, 167, syndrome 136 Deficiencies -, post-psychotic 244 Deficit symptoms , 392, 403 -, as state condition 84 -, as trait condition 84 -, post-psychotic schizophrenia, criteria 448 Deliquency 103 Denervation, chronic 391 Depression 72, 143, , 246, 280 Diachrony 14 Diagnosis - of Schizophrenia 71 Diagnostic systems 270 -, Diagnostic and Statistical Manual (DSMIIIjR) 162, 224, 270, 280 -, International Classification of diseases (lcd 9) 223 -, Present State Examination (PSE) 162, 270 -, Research Diagnostic criteria (RDC) 224, 270, 280 Disability - in social roles study 142, 162, Disability Assessment Schedule 163, Dopamine - activity ,328 - agonists, drug abuse 93 - autoreceptors 379, , hypersensitivity , subsensitivity 391 -, cortical hypothesis 377, metabolism overactivity 270, l-receptors Receptors 317, 331, system Drug - abuse , amphetamine , cocaine , dopamine agonists 93 -, antipsychotic induced symptoms response , antipsychotic 317 Dualism, ontological 97 Dyskinesia, acute 379

3 463 Educational level Emotional - blunting disturbances 232 Epilepsy, temporal lobe 297,308 Expressed emotions 102,402 Evolution of symptoms over time Evolutionism 9 Family - status 200, therapy 402 First rank symptoms 71-78, and phenomenological method 72 -, ideal types 74 -, identification in clinical practice , made thougths 75,77 -,operational definitions 72 -, rating scale 76 -, subject probability , typification statement 74 Fissure -, interhemispheric 300, 301, 303, 309 -, silvian 299, 302 Flat affect 82, , 269 Fluctuation of positive and negative symptoms 221 Follow-up studies ,243 - in child psychiatry 238 Frontal lobe area 131, , 306, 307, 309 GAS, see Global Assessment Scale Genetics , , adoption studies 265 -, and adolescent schizophrenia 232 -, and negative symptomatology 268 -, and positive symptomatology 268 -, family studies 252,265, , heritability 260, 266 -, homotypia 253 -, in psychiatry 268 -, in Schizophrenia , King's College Hospital Study , liability continuum 261 -, linkage analysis 266, 287 -, models 251 -, morbid risk of schizophrenia 256 -, phenotype, schizophrenia-related 274 -, phenotypic heterogeneity 266 -, polygenic inheritance 266 -, schizotypal marker , segregation studies 268 -, severity-liability model 135, 160, 254, ,261 -, spectrum 266 -, threshold models 254, 257, 261 -, twin data 252, 253, 258, 279 German structuralism 97 Gestalt psychology 99 Global Assessment scale , Globus pallidus 292 Group therapy 402 Growth hormone 319 Gyrus parahippocampal 305 Heterogeneity -, aetiological 250 -, clinical 250 Hippocampus 296, 307 History, conceptual 8-27 Homovanillic acid 318, 319, HVA, see Homovanillic acid Hypersensitivity -, autoreceptor hypersensitivity 390 -, post-synaptic receptor hypersensitivity 387 Hypofrontality 46, IMDS, see Inpatient Multidimensional Psychiatric Scale Inpatient Multidimensional Psychiatric Scale 54 Instrument for the retrospective assessment of the onset of schizophrenia Integrated psychological therapy Intelligence , language-independent 234 Intentionality -, amorphous counter Model IPT, see Integrated psychological therapy IRAOS, see Instrument for the retrospective assessment of the onset of schizophrenia Isolation, social 273 Laterality 297 Life-events 102 Limbic - pathway, subcortical system ,295 Locus coeruleus 325 Longitudinal research 154 Long-term course - of adolescent schizophrenia of childhood schizophrenia , follow-up studies , of schizophrenia

4 464 Magical Ideation Scale 286 Magical thinking 272 Magnet resonance imaging, see MRI Mannheim Disability Study Marker, schizotypal 278 Mental - automatism 19 - representatives 97 Mesocortical projections 390 Mesotemporal structures 307 Methylphenidate methoxy-4-hydroxyphenylglycol, see MHPG MHPG 319,326,327,328, Micropsychosis 276 Mixed schizophrenia -, course , -, stability 172, Modularity models 17 Monomorphism of course Morbid risk of schizophrenia 256 Motivation -, conceptualization 79 -, lack of 317 -, operationalization 79 MRI studies 45, 110, ,319 Negative schizophrenia -, concept , , course , -, criteria 225, 447 -, onset , outcome , premorbid features Negative Symptom Rating Scale 270 Negative symptoms -, and brain morphology 121 -, and genetics 268 -, and outcome , and treatment outcome 121 -, assessment 28-70, , , -, multi-modal approach , -, reliability 29-34, 58 -, -, validity 58, 166 -,concept 1-7,28-51, , correlation with positive symptoms , course , , definition 52, , evaluation criteria 52-70, 163 -, history 8-29, 52, 134, in adolescence schizophrenia in childhood schizophrenia 221 -, instruments of evaluation 52 -, onset 151 -,operationalisation 161 -, pathophysiological theory 391 -, primary 129 -, rating scales 55 -, secondary 129, 392 -, specifitity , stability , , test theory, classic 57 -, treatment -, - effects 36-38, , -, cognitive-behavioral psychotherapy 402 -, -, nonpharmacological concepts , -, psychological programs , - response , -, social programs , - with atypical neuroleptics , - with autoreceptor agonist , - with clozapine , - with typical neuroleptics , validity , vulnerability model 400,419 Neurasthenia 322 Neurobiochemical studies Neurological signs 131 Neuropathological studies Neuropeptids 321 Neuropsychological impairment 271 Neurosis 72 -, social 81 Neurotoxins 318 Noradrenalin 318,327, 331 -, activity 317, Dopamin connection 331 NSRS, see Negative Symptom Rating Scale Occupation at onset Oneiroid state, psychotic 99 Onset - of illness - -, late of negative symptoms of positive symptoms 151, of psychosis 154 Ontological Dualism 97 Operational Criteria Checklist for Psychotic Illness 256 Organic brain diseases 297, 308 Outcome , and negative symptoms , Global Assessment Scale , prediction , social 155, PANSS, see Positive and Negative Syndrome Scale

5 465 Passivity 322 Parahippocampal - dysfunction gyrus 305 Pathology, temporo-limbic 308 Personality -, anhedonic 81 - disorder , as-if-personalities , paranoid , schizoid , schizotypal 81, 265, 271, inventories 103 -, premorbid 103, , 221, 231, 246, 248 PET studies 46, 131, 305 Pimozide , 332 PIRS, see Psychological Impairments Rating Schedule Pleasure deficiency 81, 275 Positive and Negative Syndrome Scale 70 Positive schizophrenia -, concept , , course -, criteria 225, 447 -, onset , , outcome , premorbid features Positive symptoms -, and genetics 268 -, assessment 28-51, , -, reliability ,concept 1-7, , correlation with negative symptoms , course , definition , history 8-29, 134,442 - in childhood schizophrenia 245 -, onset 151 -,operationalisation 161 -, provocation of 115 -, specifity , stability over the course , -, treatment -, - effects 36-38, , - response , validity Positron emission tomography, see PET studies Postmortem brain studies , morphometric , qualitative 295 Poverty of speech 269 Predictors - of course 156, of outcome 156, 236, of treatment outcome 118 Premorbid - adjustment 155, features personality 103, , 221, 231, 246, 248 Prodrome 141, 328 Prognosis - of adult schizophrenia of childhood schizophrenia of mixed schizophrenia of negative schizophrenia of positive schizophrenia , poor 319 Projections -, glutamatergic 390 -, mesocortical 390 Pseudoneurotic schizophrenia 275 Psychological Impairments Rating Schedule 145, 163, 213 Psychosis 327 -, development pattern in adolescence , age of first manifestation , course in childhood , age of first manifestation , classification , course 220 -, onset 154 Psychosocial factors 293 Rating Scale for Emotional Blunting 270 Receptors -, alphal , alpha , beta , D , D2-317, 331, 378 -, Dopamin autoreceptors 379 Rehabilitation Program 231 Residual syndrome, see defect RSEB, see Rating Scale for Emotional Blunting SADS, see Schedule for Affective Disorders and Schizophrenia SANS, see Scale for the Assessment of Negative Symptoms SAPS, see Scale for the Assessment of Positive Symptoms Scale for the Assessment of Negative Symptoms 28,82, 127, 164, 166,270, 327,417

6 466 Scale for the Assessment of Positive Symptoms 28 Schedule for Affective Disorders and Schizophrenia 270 Schizophrenia -, ambulatory 276 -,concept 1-7, ,174,425,440 -, genetics 265 -, first episode 109, in childhood and adolescence , long-term course , outcome , pseudoneurotic 275 -, subtypes Schizophrenia-like psychoses, genetics 267 Schizotaxia 275 Schizo typal - marker personality disorder 265, Scheiderian first rank symptoms 270 Serotonin 320, 321 Sex - differences distribution and subtypes 199, Shift of symptoms , 223, 226, 238, Sign-field disturbances 100 Silvian fissure 299 Social - adjustment class consequences of the illness 213 Specifity - of negative symptoms of positive symptoms SPECT studies 46, 305 Speech disturbances 245 Stability of diagnosis Structural - brain abnormalities 45-46, 131,271 - distortion 101 Structured Interview for Schizotyp 286 Subcortical limbic pathway 270 Subtypes of schizophrenia 1-7, , 166, 230, 234, 238, and sex distribution , type 1/11 129, 136, 169, 251, 260 Sulci -, frontal 299, 301 -, global widening 326 -, parieto-occipital cortical 299 Symptom shift 223, 226 Symptomatology 226 -, effects of treatment 113 -, evolution over time , negative, and outcome 109, 125 Symptoms, drug-induced 328 Temporal horn 300, 302, 303, 305, 306 Temporal lobe 293, 303, 308 Thalamus 131 Third ventricle 299, 301, 303, 306 Treatment , amphetamine and symptom shift 226 -, antipsychotic drugs 84-92, , dopamine agonists , -, apomorphine 380, 382 -, -, bromocriptine 383 -, -, Roxindol (EM 49980) 387, , -, Talipexole (B-HT 920) effects - - on negative symptoms 36-38, on positive symptoms , ECT 378 -, methylphenidate , neuroleptics 110, , -, haloperidol 325 -, -, pimozide , outcome 111,121 -, psychostimulants , predictors response , acute , behavioral , - to clozapine , - to Methylphenidate , shift of symptoms 223 -, side effects -, -, akathesia 322 -, -, dyskinesia 379 -, -, parkinsonism 379 -, -, sedation, apomorphine-induced 384 Trema 99 Validity - of dichotomy models of negative symptoms of positive symptoms VBR, see Ventricles to brain ratio Ventricle, third 299, 301, 303, 306 Ventricles to brain ratio (VBR) 45, 298, 317, 328 Ventricular - enlargement system 304, 305 Viral infections 297 Withdrawal - Iretardation factor (BPRS) 322 -, social 83, 148, 272